The last earnings report on December 31 showed earnings per share of 55 cents, beating the estimate of -99 cents. P/B Ratio (3.048) is normal, around the industry mean (10.139). P/E Ratio (0.000) is within average values for comparable stocks, (115.202). MRNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.468). MRNA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (6.238) is also within normal values, averaging (226.762). With 3.21M shares outstanding, the current market capitalization sits at 42.22B.